Report Overview
The Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market is expected to grow from USD 5.92 billion in 2025 to USD 8.55 billion in 2030, at a CAGR of 7.6%.
This research study examines the idiopathic pulmonary fibrosis diagnostic and treatment market based on various segments: type and geography. First, a brief overview of the market details key driving factors and challenges. Next, Porter's five forces model analyzes the idiopathic pulmonary fibrosis diagnostic and treatment market comprehensively. This is followed by industry value chain analysis, which determines the companies that are part of the different processes and contribute to various sectors.
The study also presents in-depth information concerning the development, trends, and industry policies and regulations affecting the idiopathic pulmonary fibrosis diagnostic and treatment market. Moreover, the research study analyzes the overall regulatory framework of the idiopathic pulmonary fibrosis diagnostic and treatment market, offering stakeholders a better understanding of the key factors influencing the overall market environment.
The idiopathic pulmonary fibrosis diagnostic and treatment market is a comprehensive and latest report. It provides vital market information to executives and interested stakeholders to enable them to get vital market information. The report also analyzes the competitive landscape and details strategies of key market players, and also plots them on our vendor matrix in four quadrants: leader, follower, challenger, and niche.
The scope and coverage of the idiopathic pulmonary fibrosis diagnostic and treatment market report is as below:
Idiopathic pulmonary fibrosis diagnostic and treatment market data tables and charts
Market outlook with sections on drivers, restraints, Porter’s, and industry value chain analysis
Market assessment by type into diagnostic testing, pharmacological drugs, and surgical treatment.
A 360° view of the demand for idiopathic pulmonary fibrosis diagnostic and treatment market solutions/services across different geographies (North America, South America, Europe, the Middle East and Africa, and the Asia Pacific), with further breakdown for key countries within those regions.
Idiopathic Pulmonary Fibrosis Diagnostic And Treatment Market Scope:
| Report Metric | Details |
|---|---|
| Total Market Size in 2025 | USD 5.92 billion |
| Total Market Size in 2030 | USD 8.55 billion |
| Forecast Unit | Billion |
| Growth Rate | 7.6% |
| Study Period | 2020 to 2030 |
| Historical Data | 2020 to 2023 |
| Base Year | 2024 |
| Forecast Period | 2025 – 2030 |
| Segmentation | Type, Drug Type, Route of Administration, End-Use |
| Geographical Segmentation | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies |
|
Market Segmentation
By Type
By Drug Type
By Route Of Administration
By End-use
By Geography
Table of Contents
1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY TYPE
5.1. Introduction
5.2. Diagnostic Testing
5.3. Pharmacological Drugs
5.4. Surgical Treatment
6. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY DRUG TYPE
6.1. Introduction
6.2. Pirfenidone
6.3. Nintedanib
6.4. Others
7. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY ROUTE OF ADMINISTRATION
7.1. Introduction
7.2. Oral
7.3. Parenteral
8. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY END-USE
8.1. Introduction
8.2. Hospitals and Clinics
8.3. Ambulatory Surgical Centers
8.4. Others
9. IDIOPATHIC PULMONARY FIBROSIS DIAGNOSTIC AND TREATMENT MARKET BY GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. United States
9.2.2. Canada
9.2.3. Mexico
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Others
9.4. Europe
9.4.1. United Kingdom
9.4.2. Germany
9.4.3. France
9.4.4. Spain
9.4.5. Others
9.5. Middle East & Africa
9.5.1. Saudi Arabia
9.5.2. Israel
9.5.3. UAE
9.5.4. Others
9.6. Asia Pacific
9.6.1. Japan
9.6.2. China
9.6.3. India
9.6.4. South Korea
9.6.5. Indonesia
9.6.6. Thailand
9.6.7. Others
10. COMPETITIVE ENVIRONMENT AND ANALYSIS
10.1. Major Players and Strategy Analysis
10.2. Market Share Analysis
10.3. Mergers, Acquisitions, Agreements, and Collaborations
10.4. Competitive Dashboard
11. COMPANY PROFILES
11.1. Roche Holding AG
11.2. Boehringer Ingelheim
11.3. AdAlta
11.4. FibroGen, Inc.
11.5. United Therapeutics
11.6. Galecto Biotech
12. APPENDIX
12.1. Currency
12.2. Assumptions
12.3. Base and Forecast Years Timeline
12.4. Key benefits for the stakeholders
12.5. Research Methodology
12.6. Abbreviations
Request Customization
Tell us your specific requirements and we will customize this report for you.
Download Free Sample
Get a sample copy of this report with charts, TOC, and methodology.
Speak to Analyst
Ask our analysts any questions you have about this market research report.
Idiopathic Pulmonary Fibrosis Diagnostic And Treatment Market Report
Trusted by the world's leading organizations
